


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

(1) APPOINTMENT OF EXECUTIVE DIRECTOR

(2) CHANGE OF CHAIRMAN OF THE BOARD

AND

(3) CHANGE OF COMPOSITION OF BOARD COMMITTEE

The Board announces that with effect from 25 March 2025:

- (i) Ms. Jiang Nian has resigned from the position as the Chairman and the chairman of the Nomination Committee; and
- (ii) Dr. Yeung Yung has been appointed as an executive Director, the Chairman and the chairman of the Nomination Committee.

The board (the “**Board**”) of directors (the “**Director(s)**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Ms. Jiang Nian (“**Ms. Jiang**”) has resigned as the chairman of the Board (the “**Chairman**”) and the chairman of the nomination committee of the Company (the “**Nomination Committee**”) with effect from 25 March 2025. Ms. Jiang remains as a non-executive Director and a member of the remuneration committee of the Company.

The Board would like to express its sincere gratitude to Ms. Jiang for her invaluable contribution to the Company as the Chairman during her tenure of office.

The Board is pleased to announce that Dr. Yeung Yung (“**Dr. Yeung**”) has been appointed as the Chairman, an executive Director and the chairman of Nomination Committee with effect from 25 March 2025. The biographical details of Dr. Yeung are set out below:

Dr. YEUNG Yung (仰融), aged 67, from November 1998 to 24 March 2025, served as an executive director and the chairman of Hybrid Kinetic Group Limited (stock code: 01188) (“**Hybrid Kinetic**”), a company listed on the Stock Exchange. Dr. Yeung is also a substantial shareholder of Hybrid Kinetic. Dr. Yeung holds a PhD Degree in Economics from the China’s Southwest University of Finance & Economics. Dr. Yeung was elected as a director of the John Hopkins University Center — Nanjing University Centre for Chinese and American Studies (中美文化交流中心理事). Dr. Yeung was the chairman, chief executive officer and president of Brilliance China Automotive Holdings Limited and also the chairman and president of Shenyang Jinbei Passenger Vehicle Manufacture Co., Ltd. from 1992 to 2002. Dr. Yeung is a well-known, highly successful automotive industrialist with over 20 years’ experience in the automobile industry as well as a pioneering international financier from China.

The Company has entered into a service agreement with Dr. Yeung for his directorship commencing from 25 March 2025 for an initial term of 3 years which may be terminated by either party giving to the other not less than one month’s prior notice in writing. Dr. Yeung is entitled to a monthly salary of HK\$1,000 on a thirteen-month’ basis after considering a range of factors including his experience, his duties and responsibilities in the Group, the remuneration structure of the Group and levels of remuneration for peers in the market. His directorship is subject to retirement by rotation and re-election at the next general meeting of the Company in accordance with the bye-laws of the Company (as amended from time to time) and the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

Save as disclosed above, as at the date of this announcement, Dr. Yeung (i) has not held any positions with the Company and other members of the Group; (ii) has not held any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any other major appointments and professional qualifications; (iv) does not have any other relationship with any Directors, senior management or substantial or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

In addition, save as disclosed above, there is no other information required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in connection with the appointment of Dr. Yeung as an executive Director that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warmest welcome to Dr. Yeung on his appointment.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Tang Rong
Executive Director

Hong Kong, 25 March 2025

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Mr. Li Jiehong (executive Director), Ms. Qi Shujuan (executive Director), Ms. Jiang Nian (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) and Mr. Chen Jinzhong (independent non-executive Director).